The Library

Estimating the cost-effectiveness of detecting cases of chronic hepatitis C infection on reception into prison

Tools

Sutton, A. J., Edmunds, W. John and Gill, O. N.. (2006) Estimating the cost-effectiveness of detecting cases of chronic hepatitis C infection on reception into prison. BMC Public Health, Vol. 6 (No. 17). ISSN 1471-2458

Preview

PDF
WRAP_Sutton_Estimating_cost_effectiveness.pdf - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
Download (591Kb)

Official URL: http://dx.doi.org/10.1186/1471-2458-6-170

Abstract

Background
In England and Wales where less than 1% of the population are Injecting drug users (IDUs), 97% of HCV reports are attributed to injecting drug use. As over 60% of the IDU population will have been imprisoned by the age of 30 years, prison may provide a good location in which to offer HCV screening and treatment. The aim of this work is to examine the cost effectiveness of a number of alternative HCV case-finding strategies on prison reception

Methods
A decision analysis model embedded in a model of the flow of IDUs through prison was used to estimate the cost effectiveness of a number of alternative case-finding strategies. The model estimates the average cost of identifying a new case of HCV from the perspective of the health care provider and how these estimates may evolve over time.

Results
The results suggest that administering verbal screening for a past positive HCV test and for ever having engaged in illicit drug use prior to the administering of ELISA and PCR tests can have a significant impact on the cost effectiveness of HCV case-finding strategies on prison reception; the discounted cost in 2017 being £2,102 per new HCV case detected compared to £3,107 when no verbal screening is employed.

Conclusion
The work here demonstrates the importance of targeting those individuals that have ever engaged in illicit drug use for HCV testing in prisons, these individuals can then be targeted for future intervention measures such as treatment or monitored to prevent future transmission.

Item Type:

Journal Article

Subjects:

H Social Sciences > HN Social history and conditions. Social problems. Social reform

Divisions:

Faculty of Science > Life Sciences (2010- ) > Biological Sciences ( -2010)

Library of Congress Subject Headings (LCSH):

Hepatitis C -- Great Britain, Prisoners -- Medical care, Drug addicts -- Great Britain

Journal or Publication Title:

BMC Public Health

Publisher:

BioMed Central Ltd.

ISSN:

1471-2458

Official Date:

27 June 2006

Dates:

Date	Event
27 June 2006	Published

Volume:

Vol. 6

Number:

No. 17

Identification Number:

10.1186/1471-2458-6-170

Status:

Peer Reviewed

Access rights to Published version:

Open Access

References:

1. Limburg W: Natural history, treatment and prevention of
hepatitis C in injecting drug users; an overview. In Hepatitis C
and injecting drug use: impact, costs and policy options Edited by: Jager J,
Limburg W, Kretzschmar M, Postma M and Wiessing L. Lisbon, European
Monitoring Centre for Drugs and Drug Addiction; 2004:21-38.
2. www.hpa.org.uk. Website 2006.
3. Leal P, Stein K, Rosenberg W: What is the cost utility of screening
for hepatitis C virus (HCV) in intravenous drug users? J
Med Screen 1999, 6:124-131.
4. Agency HP, Scotland HP, National Public Health Service for Wales,
Ireland CDSCN, CRDHB, UASSG: Shooting Up; Infections among injecting
drug users in the United Kingdom 2004, An update: October 2005 London,
Health Protection Agency; 2005.
5. Weissing L, Roy K, Sapinho D, Hay G, Taylor A, Goldberg D, Hartnoll
R: Surveillance of hepatitis C infection among injecting drug
users in the European Union. In Hepatitis C and injecting drug use:
impact, costs and policy options Edited by: Jager J, Limburg W,
Kretzschmar M, Postma M and Wiessing L. Luxembourg, European
Monitoring Centre for Drugs and Drug Addiction; 2006:91-135.
6. Roy K, Hay G, Andragetti R, Taylor A, Goldberg D, Wiessing L: Monitoring
hepatitis C virus infection among injecting drug users
in the European Union: a review of the literature. Epidemiol
Infect 2002, 129:577-585.
7. de Angelis D, Hickman M, Yang S: Estimating long-term trends in
the incidence and prevalence of opiate use/injecting drug use
and the number of former users: back-calculation methods
and opiate overdose deaths. Am J Epidemiol 2004, 160:994-1004.
8. Frischer M, Hickman M, Kraus L, Mariani F, Wiessing L: A comparison
of different methods for estimating the prevalence of
problematic drug misuse in Great Britain. Addiction 2001,
96:1465-1476.
9. Skipper C, Guy JM, Parkes J, Roderick P, Rosenberg WM: Evaluation
of a prison outreach clinic for the diagnosis and prevention
of hepatitis C: implications for the national strategy. Gut
2003, 52:1500-1504.
10. Schlicting EG, Johnson ME, Brems C, Wells RS, Fisher DG, Reynolds
G: Validity of injecting drug users' self report of hepatitis A,
B, and C. Clin Lab Sci 2003, 16:99-106.
11. Reuter P: What drug policies cost: estimating government
drug policy expenditures. Addiction 2006, 101:315-322.
12. Sutton AJ, Gay NJ, Edmunds WJ, Andrews NJ, Hope VD, Gilbert RL,
Piper M, Gill ON: Modelling the hepatitis B vaccination programme
in prisons. Epidemiol Infect 2006, 134:231-242.
13. Sutton AJ, Gay NJ, Edmunds WJ, Hope VD, Gill ON, Hickman M:
Modelling the force of infection for hepatitis B and hepatitis
C in injecting drug users in England and Wales. BMC Infect Dis
2006, 6:93.
14. Macalino GE, Hou JC, Kumar MS, Taylor LE, Sumantera IG, Rich JD:
Hepatitis C infection and incarcerated populations. The International
Journal of Drug Policy 2004, 151:103-114.
15. Health Protection Agency Centre for Infections: Hepatitis C in
England: The First Health Protection Agency Annual
Report. London; 2005.
16. Best D, Noble A, Finch E, Gossop M, Sidwell C, Strang J: Accuracy
of perceptions of hepatitis B and C status: cross sectional
investigation of opiate addicts in treatment. BMJ 1999,
319:290-291.
17. Darke S: Self-report among injecting drug users: a review.
Drug Alcohol Depend 1998, 51:253-263.
18. Treasury HM: The Green Book, Apprasial and Evaluation in Central Government
2003.
19. Mortimer P: Ready, steady, go for HCV antigen testing? Commun
Dis Public Health 2000, 3:154-155.
20. Recommendations for prevention and control of hepatitis C
virus (HCV) infection and HCV-related chronic disease.
Centers for Disease Control and Prevention. MMWR Recomm
Rep 1998, 47:1-39.
21. Horne JA, Clements AJ, Drennan P, Stein K, Cramp ME: Screening
for hepatitis C virus in the Dartmoor prison population: an
observational study. J Public Health (Oxf) 2004, 26:372-375.
22. Guidance on the use of Ribavirin and Interferon Alpha for
Hepatitis C. Volume 14. National Institute for Clinical Excellence;
2000.
23. Curtis L, Netten A: Unit Costs of Health and Social Care Personal Social
Services Research Unit; 2004.
24. Stein K, Dalziel K, Walker A, McIntyre L, Jenkins B, Horne J, Royle P,
Round A: Screening for hepatitis C among injecting drug
users and in genitourinary medicine clinics: systematic
reviews of effectiveness, modelling study and national survey
of current practice. Health Technol Assess 2002, 6(31):1-122.
25. www.hpa.org.uk. Website 2005.
26. Seeff LB: Natural history of chronic hepatitis C. Hepatology
2002, 36:S35-S46.